Notes

A deepdive analysis was completed with 49.14 in cash and no orders placed. The core analysis of two stocks, 1481 and 1482, showed a loss of 1.8556% and a gain of 3.6779%, respectively. Both stocks were affected by actual approval news from the FDA, which is a government agency that approves new medicines. Ten primary cases were examined, including RAREUX111, which had an early complete response letter, and NUVL, which had an early approval. The analysis did not include any hazardous events. The actual loss on September 2 was due to another pipeline, Aspire, not UX111's FDA decision. The metadata was last updated at 16:01:36 ET. The first post had a 15-minute bar of 14.9915, which was down 43.53% from the previous price of 26.55, but this quote was not executable. Various analyses were conducted, including numbers 1402, 1488, and 1490-96, and lessons 486-488. Five existing jobs and 20 monitors were preserved. The collector showed 118 actual rows of data at 02:30, but the footer was truncated. There were no matching links for 80 FDA items at 03:15, but this was not an exhaustive search. The DRI 1376 paper from September 17-23 and earnings monitors remained unchanged. The next step is to read the actual output from the collector and maintain pending catalyst checks. Future FDA research needs to include preregistered and complete announced cohorts, including complete response letters and withdrawals. There is no forecast for future event returns from the selected cases. The scripts and results are stored in the /tmp/codex-run-MaH0rf directory if retained, and all critical figures are in observations 17167-17411. The cash decision does not require a queued order or an additional job.

An audit found errors in the consequences1403 document, which has been corrected to reference analysis1402 instead of phrase1410-equivalent. The Timing10cases in the artifacts/events.json file were also corrected, including the Gozellix notice date, which was changed from October 17 to October 23, and the MIRME earliest FDA date, which was updated to February 21, superseding the previous date of February 24. The DTX401 original notice date was confirmed to be February 23. The script analyze.py and the artifacts/results.json file contain 28 event cost rows, 8 summaries, and technical simulation data. The vectorbt cash returns were matched to the formula, with no missing price window bars. Market control and 15-minute artifacts were saved separately, and primary observations were preserved to prevent critical figure loss in case of ephemeral file system loss. Collector 118 note 1320 shows all 11 named primary panels at 02:30, with an exit code of 0. However, note truncation cut off static reminders and footers, so the log is not complete. Collector 80 note 1329 at 03:15 found the FDA panel date present, but no matching briefing links, indicating a partial scope and not proof that briefings are absent. The existing 5 jobs and 20 armed monitors were preserved, and no new prospective calendar date was discovered in this historical deep dive, requiring no trade action before 06UTC. The TLX22, MIRM14, SRRK24, and GRAL23 specifications already include early decision and full pipeline details, with no automatic entry. The DRI paper window and unarmed reminders remain unchanged. No additional collector or capacity churn is needed while the system is flat.

A tool showed that only 4 minutes had passed since the start at 04:01, correcting an earlier commentary that stated 8 minutes had elapsed. The original Gozellix PDF from October 2024 had a header date of October 17, not October 23, as previously entered. A recovered notice from DTX401 confirmed an August 2023 goal before T20, resolving an earlier entry gap. A news release from MIRM on January 13, 2025, confirmed a revised March 28, 2025 goal. The FDA PDF had an apparent typo with a 2028 date, which is not a valid date. Implementation will be frozen with specific rules: the nth SPY session must be strictly before the target, and pending entries are required. The earliest known public date must be less than or equal to the entry date to skip. There are two fixed rules for opening and closing, with fees of 10 basis points plus slippage of 10 basis points on each side. A news scan found the headline and link for the MIRM announcement at https://ir.mirumpharma.com/news/news-details/2025/Mirum-Pharmaceuticals-Announces-Preliminary-Unaudited-2024-Net-Product-Sales-and-Cash-Balance-and-Provides-Corporate-Updates/default.aspx and the DTX401 notice at https://ir.ultragenyx.com/node/18466. Daily close marking will be done with open entries and close exits via vectorbt, with no intraday stop claim. The report will include equal capital event sleeves, including idle cash, for realized tested events. The test diagnoses calendar exposure and cannot qualify 15-minute execution or the actual no-hold-through rule when early news is inside the window. No buys are authorized.

A budget of 43 minutes was allocated from 04:01 UTC, with 45 minutes of hard time and 5 minutes reserved. Previously, it was decided to exit before the PDUFA date, as it is safer, but the size of the protection is unknown. A question tree with 3 levels and at least 12 leaves was created to explore the topic. The tree has four main branches: 1) Timing mechanism, which includes goal versus promise, such as early approval or early Complete Response Letter, and observable news, like FDA action dates; 2) Selection and identification, which considers the denominator, such as all decisions or only approvals, and confounding factors, like other pipeline readouts; 3) Payoff, which looks at actual windows, like T20/T10, and execution, including overnight gaps; and 4) Generalization, which examines composition, like original or resubmission, and consequences, such as sponsor cash runway. The resolution involves analyzing calendar-day leads and daily-session returns, ignoring consensus estimates. The first step is to obtain paired advance-primary target and primary first announcement data for existing fund/watchlist issuers, including RARE, IONS, MIRM, TLX, SRRK, and NUVL. Historical cases will be used to test the safety of the approach, but whole-market hazard cannot be estimated from selected cases. A freeze price rule will be applied before viewing returns, comparing nominal-target T20 open to T6 close and T10 open to T2 close. The data will be split into 2025 for training and 2026 for holdout, if enough documented pairs are available. No strategy trading will occur unless independent evidence qualifies, and missing data will not be treated as zero. Only primary dates will be used, and both adverse and favorable cases will be retained. The research will include every measured paired date and return, and the operational allocation is currently zero.

The fund manager of the Catalyst fund, which is for research only, made some primary checks. The fund is not eligible for approval and the panel is not an approval committee. The manager compared links with prior notes. On September 9, 2026, at 03:15:51 UTC, the manager checked the FDA website for information about an upcoming meeting of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee, scheduled for September 23, 2026. The manager found that there were no matching links and the links had a SHA256 hash of 4f53cda18c2baa0c0354bb5f9a3ecbe5ed12ab4d8e11ba873c2f11161202b945. The manager also checked the SEC filings for SFIX on July 28, 2026, and LOVE on June 15, 2026. Additionally, the manager checked the RSS feed for LOVE and found an announcement about a second-quarter conference call. The manager chose to review LOVE on September 10 at 12:30 UTC and SFIX on September 24 at 12:30 UTC. The manager will monitor the companies' organic growth and cash flow, and will require independently validated net event edges. If there are any adverse, early, delayed, or absent events, the manager will stay in cash and reverify the primary date. There are no automatic orders. The manager will also check the SEC and RSS feeds, but this is not an exhaustive list.

The fund, which is called Catalyst Research, had a size of 0 at 02:30:25 on September 9, 2026. There were several news updates, including Telix completing enrollment in a Phase 3 study on September 1, 2026, and Mission Produce announcing its fiscal 2026 third-quarter financial results on September 8, 2026. Other companies that made announcements include ABM, Roivant, and UNFI. The fund also reviewed filings from DRI, PPIH, MRK, and WLTH. Additionally, the fund checked the websites of Kingfisher and Askul, which returned HTTP200, meaning the requests were successful, with specific hash values. The fund preserved information from September 8, including data on Roivant and ABM, and made decisions about AVO and TLX. The fund also considered macroeconomic data on September 8 and 9. The sources and branches of the information are noted in sections 8967-72 and 52. The fund chose to review certain items at specific times, including PP, without being armed, or taking action, at the time of the review.

A news scan found the headline was not available, but a broad scan was conducted at 04UTC. There were no proposals and the cash amount was 49.14. New primary dates were set: a DRI call on September 24 at 8:30 ET, a MRK HYPERION event on September 21, an ASKU event on September 15, and a KGF event on September 22. The PPIH and WLTH events on September 9 only have overnight or event day windows and no qualified rule. The DRI 1376 was frozen at T-5 open and T-1 close, with training results showing a 1.4581% increase, holdout results showing a 5.6622% increase, and other metrics including a mean of 0.951163% and a 95% confidence interval of -0.828497% to 2.966011%. A paper trade was simulated from September 17 open to September 23 close, but no actual entry was made. Twelve historical training notice vintages were incomplete, and six holdout advance notices were verified. Various technical, statistical, and simulation data were recorded, including 471-473 lessons. US data included 13155 unique and 12647 snapshot entries, with 384 syntax and 124 missing gaps, and 959 descriptive matches including ETFs. JPX data included 232 September event rows. A new job, 118, replaces job 52 after testing 11 panels, and will preserve original coverage of TLX, AVO, ABM, ROIV, and UNFI, and add coverage of DRI, PPIH, MRK, WLTH, KGF, and ASKU. The first sandbox output is pending, and the next run is not guaranteed. Existing jobs were not modified, except for the addition of new review reminders. The next 04UTC run will verify new primary releases without retuning. Local scripts and data are stored in /tmp/codex-run-4LVonP, and critical figures and events are persisted in observations 16251-74, 16547, and 16557, and analyses.

A standalone schedule was rejected due to having 422 too many jobs, with five active jobs already. The initial long name failed a 60 character tool validation before an Application Programming Interface call. An existing job, number 52, has 7 runs left at a 240 minute cadence and the original script was saved from a fund-scoped list of jobs. A tested combined 11 panel replacement is being prepared, which will preserve its TLX, AVO, ABM, and ROIV RSS and UNFI filing checks, as well as all dated reminders. This replacement will also add DRI, PPIH, MRK, and WLTH filings, and KGF and ASKUL calendars. Only after the combined test succeeds will job 52 be cancelled and replaced. This is a capacity management decision, not an automatic approval rejection, and no orders or other fund jobs are affected.

A test was done on a python script called collector.py after changing the news sources for MRK and WLTH404 to use SEC submissions instead. The test included the four most recent filings from DRI940944, PPIH914122, MRK310158, and WLTH1524566, as well as the calendars of KGF and ASKUL issuers. The test declared a User-Agent, set 15-second timeouts, allowed three requests at the same time, and included explicit statuses and calendar hashes with an END6 footer. This test may not catch news from issuers before they file and cannot confirm the outcome of an FDA decision. Reminders were set for the following times: PPIH on September 9 at 12:30 UTC, WLTH on September 10 at 12:30 UTC, ASKUL on September 15 at 12:30 UTC, MRK on September 18 at 12:30 UTC before the September 21 goal, KGF on September 22 at 12:30 UTC provisionally, and DRI on September 24 at 12:30 UTC. These dates come from observations 16089, 16110, 16279-81, and 16490-91. All possible outcomes, whether favorable, adverse, or delayed, are for research only and will not result in any automatic orders. A request to set a monitor for DRI was rejected with a 422 error due to too many monitors, so reminders should not be armed. The plan is to schedule a separate collector and keep the five existing Catalyst jobs.

A news scan found the following information about Darden Restaurants, which is referred to by its stock ticker DRI. The company had 18 actual SEC earnings releases from 2022 to June 2026, with 16251 to 74 individual observations confirmed. There were 12 training notice vintages that were incomplete, resulting in a full history test retrospective eligibility gap. Six holdout advance notices were verified, including notices from February 20 to March 20, 2025, May 22 to June 20, 2025, August 21 to September 18, 2025, November 20 to December 18, 2025, February 19 to March 19, 2026, and May 28 to June 25, 2026. All of these notices were for conference calls at 8:30 ET on the specified dates. The current notice is for August 27, with a paper window starting on September 17 and closing on September 23. The primary rule and six holdout outcomes were frozen, with no alternative picked using the holdout. There was no entry today, even if the edge passed, because the window starts on September 17. A monitor attempt was rejected due to a 20 armed cap, and the review is un armed, pending collector fallback. There was no guessed date or hold through.

This is a preregistered independent earnings-window test for DRI. Before looking at DRI's price history, the test will verify the issuer's earnings dates from 2022 to 2026, using dates with original advance notices known at least 5 sessions before the event. The test will follow a fixed rule: buy at the open 5 days before the event and sell at the close 1 day before the event, never holding through the event. The test will be trained on data from 2022 to 2024 and will use untouched data from 2025 to 2026 as a holdout. The baseline assumptions include 10 basis point fees and 10 basis point slippage on each side, with a stress test of 10 basis point fees and 25 basis point slippage on each side. The test will also include a sensitivity sweep of different training periods, including T-3, T-5, and T-10, and exit periods, including T-1 and T-2, but the primary test will use T-5 and T-1 and will not use the holdout data to choose the best approach. The test requires an event sample of at least 20 and will separate the results if the advance notice history is missing. The test will use daily bars and will not validate 15-minute stops. The test requires a positive expectancy and uncertainty in the holdout period, as well as affordability of the actual window and whole-share, before making any proposal. The test will also keep the Merck label expansion distinct from earnings and will not use any potential edge from DRI.

The trading plan started on September 9 at 02:00:48 UTC and had a hard stop at 02:45:48, with a planned duration of 43 minutes, including a final 5 minutes. The plan began with $49.14 in cash, aiming for a positive and repeatable pre-event expectancy, with a binding constraint based on independent actual-window evidence. The plan considered daily sessions and original release dates, discarding intraminute noise except for execution validation. A question tree was used to guide the plan, which included the following questions: 1. Was the universe of potential investments missed? This included checking the US census for listing completeness and dated issuer event intersection, as well as global original calendars and venue/FX eligibility, and crypto earnings/FDA linkage versus mandate creep. 2. What makes a date investable? This included considering timing, such as notice known before entry and early competing pipeline news, business factors like organic cash bridge and funding and dilution, and market factors like range/liquidity and costed exits. 3. Can evidence defeat zero size? This included statistical considerations like chronological holdout and selected sample/multiple tests, risk factors like gap stress and quarterKelly, and off-run factors like verified collector output and review reminders versus first news. The plan applied lessons 454-456 and did not revive failed rules through retuning. There were no holdings in the queried ledger, and all losses were closed, with the operator censoring 2.

The fund is called Catalyst Research and its size is 0 as of September 9, 2026, at 01:45:29 UTC. A news scan found the headline that Telix completed enrollment in Phase 3 BiPASS on September 1, 2026. Another news scan found the headline that Mission Produce announced its fiscal 2026 third quarter financial results on September 8, 2026. ABM reported its fiscal third quarter 2026 results on September 8, 2026. Roivant announced positive results from the PHocus study on September 8, 2026. The SEC website has a filing from UNFI on September 8, 2026. Roivant's earnings were reviewed on September 8 at 10:30 UTC, with a call at 12:00 UTC and an earnings report at 10:15 UTC. The PHocus study had primary and secondary endpoints, including a 6-minute walk test. The earnings schedule includes ABM and UNFI in the morning and AVO after close on September 8, with reviews at 12:30 UTC on September 8 for ABM and UNFI, and on September 9 for AVO. There are also macro events scheduled, including a QFR at 14:00 UTC and an SCE at 15:00 UTC on September 8, and an ECEC and QSS on September 9. All branches of the decision tree require recording primary data and verifying the date if the outcome is favorable, and cashing out if it is adverse or delayed. The decision tree does not include orders. The update ends with 4 RSS feeds and 1 SEC filing, and includes static reminders that are not exhaustive.

The fund is called Catalyst Research and it has no size. On September 9, 2026, at 00:45:24 UTC, the fund manager made some notes. There are some updates about the companies Scholar Rock, Scholastic Corporation, and Praxis Precision Medicines. On September 2, 2026, Scholar Rock received FDA Fast Track Designation, which is a special status that helps the development of certain drugs. On August 27, 2026, Scholar Rock announced that it would present at upcoming investor conferences. On August 21, 2026, Scholar Rock provided an update on its global apitegromab regulatory strategy. On September 3, 2026, Scholastic Corporation announced the date for its first-quarter fiscal 2027 results. On September 3, 2026, Praxis Precision Medicines announced inducement grants. The fund manager also reviewed a SEC filing from August 6, 2026, for Scholar Rock. The manager will review some data on certain dates: September 9, September 10, and September 29 for Scholar Rock, and September 24 and September 25 for Scholastic Corporation. The manager will also review some data for Praxis Precision Medicines on December 27. The manager will make decisions based on the data, but the decisions will not be made automatically. The manager will use the data to decide whether to record the results or to verify them again. The notes also mention that the fund has 3 shares of Scholar Rock, 1 share of Scholastic Corporation, and 1 share of Praxis Precision Medicines, and 1 SEC filing.

The Catalyst fund is doing research on IONS, MIRM, and GIS. The fund size is 0. The current time is 2026-09-09T00:30:27.576388+00:00. There are SEC filings for IONS on 2026-09-04, MIRM on 2026-09-08, and GIS on 2026-07-01. A news scan found the headline that Morgan Stanley maintains an overweight rating on Ionis Pharmaceuticals and lowers the price target to $104 on 2026-09-08. There was a conference on September 8, 2026, at 19UTC, and another event is scheduled for September 23, 2026, at 13UTC. The fund will review the companies' performance, and if the review shows improving organic volume or cash, or new guidance, it will record the evidence and require an independent cost analysis. If the review shows weak or delayed information, it will retain cash. The baseline for FY27 is an EPS of $3.00-3.20, organic growth of -1.5 to +0.5%, and savings of $750 million. The fund will verify the full biotech pipelines and early decisions, but will not make automatic trades. This review is not exhaustive and includes 3 filing checks, 1 headline lead, and 2 GIS reminders.

The automated trading fund manager reports no new proposals. The fund has $49.14 in cash and no current holdings or pending orders. New observations, including numbers 16011 through 16019 and 16039, have been recorded along with various analyses. The full release of BRZE, found at https://www.sec.gov/Archives/edgar/data/1676238/000167623826000039/a20260731-brazeincxq227ear.htm, is now accessible, showing sales of $227.23 million, with 66.8% from GM, $35.661 million from SBC, and $21.744 million in free cash flow, which is a measure of a company's profitability. The full release for GME, at https://www.sec.gov/Archives/edgar/data/1326380/000132638026000050/a991-fy26q2earningsrelease.htm, includes tables showing a second-quarter free cash flow of $60.7 million, a 46.4% decrease, and retail operating profit of $160.2 million, which is within preliminary estimates. The fund's cash and marks do not show any Bitcoin spot transactions. The TLX first-half results support a bear case, with $40 million upfront and $52 million in EBITDA, which is a measure of a company's overall financial performance, and a $23 million loss in TMS. The goal for September 11 remains unchanged, with no decision made in the absence of certain information. The fiscal change for FDX invalidates the old-calendar September estimate, but the exact new release date has not been verified. Certain expectancy models, including AVO1158 and TLX500, remain rejected. The next update will be at 02UTC, with job outputs at 00:15, 00:30, and 01:30. There are 20 armed monitors retained, with no monitors due before 02UTC. Fifteen out of 17 items need next-day context, and static overflow is explicitly unarmed. A retrieval time correction for 16019 supersedes previous estimates for 16012 through 16017. Research was finished early, and no additional time was needed. No new backtest, technical, or Monte Carlo analyses were claimed for ineligible entries.

The research started with $49.14 in cash and no holdings. The goal is to make repeatable gains before an event happens. A binding constraint is an independent edge within a specific time frame. Previous rules that failed suggested keeping cash, but those rules are being set aside to collect new facts and ignore funding pressure. The research will look at issuer disclosures up to September 9 at 00UTC, ignoring minute-by-minute changes. A question tree was created: 1. What evidence could change the current theses? This includes looking at BRZE quality, such as the split between organic and acquisition growth, and the difference between GAAP, SBC, and cash bridge, which refers to a method of calculating a company's value. It also includes looking at GME quality, such as the difference between operating and investment profits, and the risks associated with cash and receivables. Additionally, it includes looking at biotech, such as early decisions and the full pipeline, and the hierarchy of endpoints and manufacturing. 2. What makes old events worth trading? This includes looking at the new calendar, such as the exact date of an event, and the difference between a release and a call, as well as prior news. It also includes looking at payoffs, such as frozen chronological holdout and costs, and gaps and 15-minute execution, which refers to the time it takes to execute a trade. Furthermore, it includes looking at capital, such as the mean win/loss, and Kelly, fund, and whole-share caps, which refer to methods of managing risk. 3. What could change the decision to keep cash? This includes looking at a new regime, such as an independent sample, and selection bias, which refers to a distortion in the way data is collected. It also includes looking at coverage, such as global issuer calendars, and crypto only with a mandate-relevant date and edge. Additionally, it includes looking at off-run, such as collector actual output, and armed vs static reviews, which refer to methods of analyzing data. Lessons 448-450 will be applied, and rejected rules will not be automatically brought back.

The fund manager of the Catalyst fund, which is for research only, performed primary checks on Galleri, Love, and SFIX. The manager found that the panel is not an approval, and compared links with prior notes. On September 8, 2026, at 23:01:05 UTC, the manager checked the FDA website and found no matching links, with a links SHA256 of 4f53cda18c2baa0c0354bb5f9a3ecbe5ed12ab4d8e11ba873c2f11161202b945. The manager also reviewed SEC filings for SFIX on July 28, 2026, and LOVE on June 15, 2026. Additionally, the manager checked an RSS feed from LOVE, which announced a second-quarter conference call. The manager chose to review LOVE on September 10 at 12:30 UTC and SFIX on September 24 at 12:30 UTC. The manager will monitor these companies for improving organic growth and cash, and will require independently validated net events. If there are adverse or early events, the manager will stay in cash and reverify the primary date. There are no automatic orders. The manager also checked two branches, but the results are not exhaustive.

The fund in question is the Catalyst Research fund, which has a size of 0 and a UTC time of 2026-09-08T21:30:29.281842+00:00. A news scan found the headline that Telix Completes Enrollment in Phase 3 BiPASS, which was announced on Tuesday, 01 Sep 2026 22:25:55 +0000, and can be found at https://telixpharma.com/news-views/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway/. Another news scan found the headline that Mission Produce Announces Fiscal 2026 Third, which was announced on Tuesday, 08 Sep 2026 16:05:53 -0400, and can be found at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial. ABM Reports Fiscal Third Quarter 2026 Results, which was announced on Tuesday, 08 Sep 2026 06:58:07 -0400, and can be found at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results. Roivant Announces Positive Results from PHocu, which was announced on Tuesday, 08 Sep 2026 06:00:31 -0400, and can be found at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat. The SEC filing for UNFI can be found at https://www.sec.gov/Archives/edgar/data/1020859/000102085926000022/unfi-20260903.htm. On September 8, the earnings report for ROIV was released at 10:15 UTC, with a call at 12:00 UTC, and a review at 10:30 UTC. The PHocus study had primary and secondary results, which can be compared to cutoff, N, missingness, and safety. There are no remaining run-up sessions. The static earnings schedule includes ABM and UNFI in the morning of September 8, and AVO after close, with reviews at 12:30 UTC on September 8 for ABM and UNFI, and 12:30 UTC on September 9 for AVO. The goal for TLX is September 11, but earlier decisions are possible. The static macro schedule includes QFR at 14:00 UTC, SCE at 15:00 UTC, and credit at 19:00 UTC on September 8, and ECEC and QSS at 14:00 UTC on September 9. The agency URLs and periods can be found in the September 7 observations 8967-8972. All branches require favorable results to record full primary data and independent net edge, while adverse, delayed, or absent results require cash and reverify date. No orders are made. The update ends with 4 RSS and 1 SEC, and includes static reminders that are not exhaustive.

The automated trading fund manager's run on September 8 at 21UTC is complete as of 21:06. The run was under the planned 35 and hard 45 limits. There were no proposals made during this time. The fund currently has $49.14 in cash and no open, pending, or closing positions. The manager has made 20 observations and no armed trades are due through 00UTC. The manager reviewed results from AVO and CASY. AVO's actual issuer RSS results were released at 16:05:53 ET on September 8, which included a 9.9% increase in revenue and a reaffirmed EBITDA of $84-88 million for the second half of the year. CASY's results were also released, with an EPS of $7.37 and an unchanged guide. The manager also reviewed GME's results, which included an operating profit of $160.2 million, and BRZE's results, which were not fully reviewed due to a 403 error. The manager has scheduled several jobs to run at 00UTC, including job 52 at 21:15 and job 80 at 23:00. The manager has chosen to run job 52 unarmed at 12:30 UTC on September 9. No new monitors or jobs are needed, and the existing five jobs will be retained. The manager will conduct further research on the full original and replay data if accessible. The AVO position has been frozen at 1158 N6-7 with a 3.318% expectancy and a quarter Kelly of 0, which remains unchanged.

The automated trading fund manager starts with $49.14 in cash, aiming for repeatable net gains before events, considering funding pressure. The manager reviews research from after-hours trading through 00UTC, ignoring unverified headlines and minute-by-minute noise. The decision tree has three parts: Changed operating evidence, Eligible edge, and Off-run coverage. Changed operating evidence includes analyzing results from AVO, BRZE, and GME/CASY, such as comparing issuer releases to scheduled calls, price and volume changes, and growth types. Eligible edge considers saved tests, live history, and position sizing using metrics like mean win and loss, and risk caps. Off-run coverage reviews the ledger, monitors, and collectors, including holdings, pending trades, and delivery schedules. Lessons 430 to 432 are applied, and there is no new search for parameters to save a rejected rule.

The fund, which is based on catalyst research, has a size of 0 and a UTC time of 2026-09-08T20:30:32.088004+00:00. There are SEC filings for HITI on 2026-08-31 and BFRI on 2026-08-13. Dave & Buster’s Entertainment, Inc, which is ticker symbol PLAY, will report its second quarter results on September 1, 2026. The fund has chosen to review certain stocks, including TSM on September 10, DATA.L on September 14, and ET.TO on September 15, but these dates are not guaranteed and require revalidation. New reviews include CAN on September 8, PLAY on September 15, and EGTX.ST on September 25. The fund will record organic cash and clinical evidence, but will not make automatic orders. A decision on PLAY was rejected, with a confidence interval of -4.48% to 7.25%. An early decision on EGTX is possible. The fund has 48 MFN counts for EGTX, with the latest update on September 2026. The fund will review EGTX on September 11 and 16, and again on September 25 before the FDA decision on September 28. If there is a new label, PRV, or cash, the fund will record and validate it, but if there is adverse or delayed news, the fund will stay in cash and reverify.

The Catalyst fund is researching Ionis Pharmaceuticals, Mirum Pharmaceuticals, and General Mills, with a current size of 0. The research is based on data available as of September 8, 2026, at 20:15:39 UTC. The fund reviewed SEC filings from Ionis Pharmaceuticals on September 4, 2026, Mirum Pharmaceuticals on September 8, 2026, and General Mills on July 1, 2026. A news scan found the headline that Morgan Stanley maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $104 on September 8, 2026. The fund also noted that General Mills will webcast its remarks at the Barclays Global Consumer Staples Conference on September 8, 2026, and will webcast its fiscal 2027 first-quarter earnings results on September 23, 2026. The fund's strategy is to either review improving organic volume or cash and guidance, or retain cash if the information is weak or delayed. The baseline for General Mills is a fiscal year 2027 EPS of $3.00-3.20, organic growth of -1.5% to +0.5%, and savings of $750 million. The fund will verify the full biotech pipelines and early decisions, but will not make any automatic trades.

The trading fund manager's handoff at 21UTC was flat. A reaffirmation of GIS was verified, but a replay gap remains. On September 8, pre-close procedures were completed at 19:44UTC, with 35 planned and 45 hard stops. There were no proposals, $49.14 in cash, and no open, pending, or closing positions. The manager had 20 own armed positions with none due, and 5 active jobs. Observations were made from 15931 to 15934, and analyses were conducted from 1232 to 1233. A new GIS primary release was found at https://www.businesswire.com/news/home/20260908596763/en/, which reaffirms a fiscal year 2027 organic growth rate of -1.5% to +0.5%, EPS of $3 to $3.2, and FCF conversion of 95%. The original release was verified, but the fireside replay was not reviewed due to dynamic empty requests and a 403 error, which is not evidence of no remarks. The GIS stress test resulted in a -2.405% expectancy, and the AVO expectancy was -1.2126%, with a Kelly criterion of 0, which was rejected. The next inspection is scheduled for 21UTC, with 48 jobs scheduled for 20UTC and 75 jobs scheduled for 20:15. The manager will manually check AVO after close and review the original results at 17ET. AVO was chosen for review on September 9 at 12:30, and the GIS, LOVE, and SFIX overflow positions remain unarmed. The earliest own armed position is CHWY on September 9 at 12UTC. Positive updates will be recorded and independently validated, and adverse or delayed updates will be reverified. No execution is needed while the market is flat, and no collector modification is required for this run.

Before making a decision to close, the automated trading fund manager will review existing evidence. Previously, the fund had a failed run and saved run-ups that were rejected, and it set aside monthly recovery pressure. The fund started with $49.14 in cash and aimed to achieve repeatable net gains before events, with a binding constraint of having a positive independently validated expectancy. The decision will be made at 21:00 UTC during the next run, not based on minute-by-minute market changes. The manager will consider the following questions: 1. Has the evidence changed? This includes checking the GIS conference for actual remarks versus notices, and organic demand versus portfolio effects. It also includes checking AVO for early release and date or call distinction, and biotech collectors for new outcomes versus administrative filings. 2. Are the trades eligible? This includes checking saved tests for out-of-sample costs and actual remaining entry window, live trades for operator censoring and gap loss, and size for quarter Kelly and fund or risk caps. 3. Is everything covered? This includes checking the ledger for holdings and pending or closing trades, monitors for due and overflow unarmed, and jobs for actual complete output and next schedule versus guaranteed delivery. The manager will apply lessons 418 to 420 and will not retune a failed rule during the trading run.